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Selective localization of IgG from
cerebrospinal fluid to brain parenchyma
Marlene Thorsen Mørch1, Sofie Forsberg Sørensen1, Reza Khorooshi1, Nasrin Asgari1,2 and Trevor Owens1*
Abstract
Background: Encounter of autoantibodies with specific antigens can lead to hypersensitivity reactions and pathology. In
multiple sclerosis and neuromyelitis optica spectrum disease (NMOSD), immunoglobulin-G (IgG) deposition has been
observed in pathological lesions in the central nervous system. The paradigmatic autoantibodies in NMOSD are specific
for the water channel aquaporin-4, localized to astrocytic end-feet at the blood-brain barrier and ependymal cells at the
cerebrospinal fluid-brain barrier. We have previously observed that IgG antibodies from NMO patients (NMO-IgG) access
brain parenchyma from the cerebrospinal fluid and induce subpial and periventricular NMO-like lesions and blood-brain
barrier breakdown, in a complement-dependent manner.
Objective: To investigate how IgG trafficking from cerebrospinal fluid to brain parenchyma can be influenced by injury.
Methods: IgG from healthy donors was intrathecally injected into the cerebrospinal fluid via cisterna magna at 1, 2, 4, or
7 days after a distal stereotactic sterile needle insertion to the striatum.
Results: Antibody deposition, detected by staining for human IgG, peaked 1 day after the intrathecal injection and was
selectively seen close to the needle insertion. When NMO-IgG was intrathecally injected, we observed complement-
dependent NMO-like pathology (loss of aquaporin-4 and glial fibrillary acidic protein) proximal to the insertion site, with
similar kinetics. A fluorescent tracer did not show the same distribution indicating IgG-selective localization.
Conclusion: These findings suggest that IgG from cerebrospinal fluid localize selectively in brain parenchyma at the site
of injury and pathogenic NMO-IgG induce astrocyte pathology at the same location.
Keywords: Immunoglobulin-G, Cerebrospinal fluid, Neuromyelitis optica spectrum disorders, Pathology, Deposition
Introduction
Inflammatory demyelinating diseases of the central nervous
system (CNS) result in destruction of the myelin sheath
and nerve fibers, which results in disability [1]. Whereas
multiple sclerosis (MS) is considered a disease with myelin-
directed immunity, in neuromyelitis optica spectrum dis-
ease (NMOSD), astrocytes are the primary target of the im-
mune response [1, 2]. In NMOSD, the target antigen is
identified as aquaporin-4 (AQP4) [3]. In the CNS, AQP4 is
expressed by astrocytes and localized to astrocytic end-feet
at the blood-brain barrier (BBB) and ependymal cells at the
cerebrospinal fluid (CSF)-brain barrier [4, 5]. NMOSD le-
sions are predominantly located at the optic nerve or spinal
cord, but specific brain MRI abnormalities including
brainstem lesions are being increasingly recognized [6, 7].
Elevated titers of immunoglobulin-G (IgG) are seen in CSF
in MS [8] and during relapse in NMOSD [9]. In NMOSD,
anti-AQP4 antibodies in the CSF correlate with astrocyte
damage, the primary pathologic process [10]. Deposition of
IgG and complement is observed in NMOSD pathological
lesions [11], as well as in a subset of MS patients with pat-
tern II lesions [12]. There is a need for better understanding
of the clinical relevance of antibodies in CSF and how they
access the parenchyma.
Several animal models have been developed to examine
the mechanism behind NMO-like pathology [13–16]. We
have demonstrated that antibodies from NMO patients
(NMO-IgG), with human complement that was intra-
thecally injected into the CSF via cisterna magna, induced
NMO-like lesions with loss of AQP4 and glial fibrillary
acidic protein (GFAP). These lesions co-localized with de-
position of human IgG and activated complement.
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Notably, lesions were widespread in the brain paren-
chyma, and lesion location varied from mouse to mouse
[15]. We showed that antibodies from the CSF were de-
posited via a paravascular route in subarachnoid and sub-
pial space and in the periventricular region. Perivascular
deposition was specific for NMO-IgG [14]. We further ob-
served that NMO-IgG induced local complement-
dependent loss of BBB integrity at specific but variable
sites within brain parenchyma [14].
There is broad consensus that AQP4/NMO-IgG ini-
tially enters the brain via BBB-deficient sites such as area
postrema, where access to CSF occurs [17]. NMO-IgG
from the CSF gains access to the brain parenchyma and
induces NMO-like lesions [15], with BBB disruption, via
a specific IgG distribution pattern [14]. There is a need
for further studies of pathogenic mechanism of IgGs and
a better comprehension of what influences distribution
of CSF-derived IgG in the parenchyma, to help under-
stand how this site specificity is determined. Whether
and how fluid flow occurs from CSF to CNS paren-
chyma is currently under debate [18–20]. Because little
is known about what determines CSF IgG distribution in
parenchyma, we examined if external factors, such as a
sterile needle insertion, could influence the distribution.
Materials and methods
Animals
Adult female C57Bl/6J mice (Taconic, Lille Skensved,
Denmark) were housed in The Biomedical Laboratory,
University of Southern Denmark. Forty-six mice were in-
cluded for examination of IgG or dextran distribution
while four mice, one sample per brain hemisphere, were
included for the gene expression analysis.
Sterile needle insertion
Mice were anesthetized by isoflurane inhalation. Stereo-
tactic coordinates were 2 mm lateral from bregma and
0.2 mm anterior. A 30-gauge needle attached to a 50-μl
Hamilton syringe was inserted 3.5 mm in the right
hemisphere into the striatum. Ten microliters of PBS
was infused (2 μl/min) following needle insertion. After
injury, mice received Temgesic (RB Pharmaceuticals
Limited, Berkshire, UK) for pain relief and isotonic NaCl
subcutaneously to prevent dehydration.
Intrathecal delivery
One, 2, 4, or 7 days after the sterile needle insertion, a
30-gauge needle (bent at 55°, 2–2.5 mm from the tip) at-
tached to a 50-μl Hamilton syringe was inserted between
the skull and the cervical vertebra into the intrathecal
space of the cisterna magna. Three hundred micrograms
of human antibodies either NMO-IgG or normal-IgG
[15] and 288 μg complement protein isolated from
healthy donors or 125 μg Dextran, fluoresceinated,
40,000 MW (Molecular Probes, Life Technologies, Eu-
gene, OR, USA) in a total volume of 10 μl. Anesthesia
and analgesia were as described above.
Tissue processing
Mice were euthanized by an overdose of sodium pentobar-
bital and subsequently perfused transcardially with ice-cold
PBS (10 ml) followed by 4% paraformaldehyde in PBS
(20 ml). After removal, brains were post-fixed in 4% PFA,
immersed in 30% sucrose in PBS for up to 2 weeks at 4 °C,
then frozen in cryostat embedding medium (Killik, Milano,
Italy) by immersion in 2-methylbutane (Sigma-Aldrich,
Denmark) in liquid nitrogen. For examination of dextran
diffusion, whole cerebra were cut serially into 30-μm cor-
onal sections on a Micron HM 550 cryostat (Microm Inter-
national GmbH, Walldorf, Germany). For examination of
IgG diffusion, 16-μm sagittal or coronal serial sections
through the lesion were cut on a Micron HM 550 cryostat.
For examination of NMOSD-like pathology (loss of AQP4
and GFAP, deposition of IgG and C9neo, and BBB disrup-
tion), sagittal serial sections (50, 30, and 16 μm) were cut
through the lesions. For examination of gene expression
levels, mice were perfused with PBS, and a tissue block that
included the needle insertion was stored in TRIzol reagent
(Invitrogen-Molecular Probes, Eugene, OR, USA). For
examination of BBB disruption, mice were intravenously
injected with 2 mg horseradish peroxide (HRP) 15 min be-
fore perfusion.
Immunohistochemistry
CNS tissue was evaluated for deposition of human IgG
and C9neo, loss of AQP4, and GFAP staining.
Sections were dried then washed in PBS followed by
three times wash in PBS containing 0.2% Triton X-100
(Sigma-Aldrich, St. Louis, MO, USA) (PBST). Sections were
then blocked for endogenous peroxidases by immersion in
methanol containing 0.2% H2O2 (Sigma-Aldrich, St. Louis,
MO, USA) for 30 min at room temperature. Sections were
thereafter washed in PBST three times. Unless otherwise
stated, washes were carried out three times and all incuba-
tions were at room temperature. After washing, sections
were blocked for non-specific staining with 3% bovine
serum albumin (Sigma-Aldrich, St. Louis, MO, USA) in
PBST for 30 min. Sections were incubated for 1 h with pri-
mary antibody (rabbit anti-AQP-4 (1:400) (Alomone Labs
Ltd., Jerusalem, Israel), rabbit anti-GFAP (1:1000) (DAKO
Denmark A/S, Glostrup, Denmark), rabbit anti-human IgG
(1:200) (Abcam, Cambridge, UK), rabbit anti-C9neo (1:100)
(Abcam, Cambridge, UK)). To verify antibody specificity,
sections were incubated with corresponding concentrations
of rabbit immunoglobulin fraction (DAKO Denmark A/S,
Glostrup, Denmark). Sections were then washed in PBST
and incubated for 1 h with secondary antibody (biotinylated
goat anti-rabbit IgG (1:2) (Abcam, Cambridge, UK)). After
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washing in PBST, sections were incubated for 1 h with
streptavidin-horseradish peroxide (1:200, GE Healthcare,
Little Chalfont, Buckinghamshire, UK). Afterwards, sections
were washed in PBS and developed by adding 3,3′-diami-
nobenzidine (DAB, 0.5 mg/ml) (Sigma-Aldrich, St. Louis,
MO, USA) and H2O2 (0.033%) (Sigma-Aldrich, St. Louis,
MO, USA) for 2 min and washed twice in PBS. Finally, sec-
tions were dehydrated using increasing concentrations of
ethanol, cleared in xylene, and mounted using DPX mount-
ing medium (Merck KGaA, Darmstadt, Germany).
IgG deposition, BBB disruption, and loss of AQP4
staining were analyzed on full series (between 12 to 30
sections), while GFAP loss and deposition of C9neo were
examined on corresponding sections. Images were ac-
quired using an Olympus BX51 microscope with an
Olympus DP73 camera (Olympus, Ballerup, Denmark)
and analyzed using the free software Fiji.
Immunofluorescence staining
Dextran diffusion was investigated by co-staining for
GFAP to identify the needle insertion. Slides with brain
sections were dried and washed once in PBS and then
three times in PBST. Sections were blocked for non-
specific staining as above then incubated for 1 h with
anti-GFAP (1:1000, Cy3) (Sigma-Aldrich, St. Louis, MO,
USA). Slides were then washed once in PBS, then 5 min
in PBS containing 300 nM 4,6-diamidino-2-phenylindole
(Invitrogen) to stain nuclei, then washed in PBS and
mounted using gelvatol [21].
Dextran diffusion was analyzed on a full series (approxi-
mately 40 sections). Images were acquired using an Olym-
pus BX51 microscope with an Olympus DP73 camera and
analyzed using Adobe Photoshop CS3 version 10.0.
RNA extraction, reverse transcription, and quantitative
reverse transcriptase/real-time PCR
RNA was extracted using TRIzol reagent (Invitrogen-Mo-
lecular Probes, Eugene, OR, USA) in accordance with the
manufacturer’s protocol. One microgram of total RNA was
reverse transcribed using M-MLV reverse transcriptase
(Invitrogen) according to the manufacturer’s protocol. Pri-
mer and probe sequences were as follows: angiotensinogen
(AGT) (forward TGAACAACATTGGTGACACCAA, re-
verse CTGCTTTGAGTTCGAGGAGGAT, probe TGGGA
GAGGTTCTCAATAG MGB), angiotensin-converting en-
zyme (ACE) (forward CCTCTGCCTGGGACTTCTACA,
reverse CGTGACCCGTGTGCATTG, probe AAG-
GACTTCCGGATTAA MGB), renin (forward GCACCTT-
CAGTCTCCCAACAC, reverse CCCGGACAGAAGGCA
TTTT, probe CTTTGAACGAATCCCGC MGB), IFNγ
(forward CATTGAAAGCCTAGAAAGTCTGAATAAC,
reverse TGGCTCTGCAGGATTTTCATG, probe TCAC-
CATCCTTTTGCCAGTTCCTCCAG MGB), interleukin
(IL)-4 (forward ACAGGAGAAGGGACGCCAT, reverse
GAAGCCCTACAGACGAGCTCA, probe TCCTCACAG-
CAACGAAGAACACCACA MGB), IL-10 (forward
GGTTGCCAAGCCTTATCGGA, reverse ACCTGCTC
CACTGCCTTGCT, probe TGAGGCGCTGTCATCGAT
TTCTCCC MGB), TGFβ (forward TGACGTCACTG-
GAGTTGTACGG, reverse GGTTCATGTCATGGATG
GTGC, probe TTCAGCGCTCACTGCTCTTGTGACAG
MGB), TNFα (forward CCAAATGGCCTCCCTCTCAT,
reverse TCCTCCACTTGGTGGTTTGC, probe CTCA-
CACTCAGATCAT MGB), and iNOS (gene expression
assay kit from TaqMan, Applied Biosystems Inc., Foster
City, CA, USA). Samples were run as triplicates on an ABI
Prism 7300 Sequence Detection System (Applied Biosys-
tems Inc.). Results were expressed relative to 18S rRNA
(2ΔCT method) as endogenous control (TaqMan® Riboso-
mal RNA control reagents kit; Applied Biosystems Inc).
CDNA was diluted 1:1000 for 18S rRNA analysis.
Statistics
Data was analyzed by nonparametric Mann–Whitney t
test using GraphPad Prism version 4 (GraphPad Soft-
ware Inc., San Diego, CA, USA). Data are presented as
mean ± SEM. Values of p < 0.05 were considered statisti-
cally significant.
Results
Needle insertion into the brain parenchyma influences
IgG trafficking
Groups of C57BL/6 mice received normal-human-IgG into
the CSF by intrathecal injection 1, 2, 4, or 7 days post
stereotactic insertion of a sterile needle to striatum. Histo-
pathological analysis showed significant deposition of hu-
man IgG in the ipsilateral hemisphere compared to the
corresponding area in the contralateral and a lack of stain-
ing following intrathecal injection of PBS (Fig. 1a–f). IgG
deposition was localized to the area immediately proximal
to needle insertion. Controls for non-specific staining were
negative (not shown). Immunohistochemical analysis re-
vealed that IgG deposition in the area around the needle in-
sertion was strongest at 1 day (Fig. 1a) and was gradually
reduced at 2, 4, and 7 days after the needle insertion (Fig.
1b–d). Hematoxylin and eosin staining at the time point for
the strongest IgG deposition revealed only few infiltrating
cells in the area where IgG was deposited (not shown).
Among inflammation-associated cytokines (IFNγ, IL-4, IL-
10, TGFβ, TNFα), only TNFα showed a significant upregu-
lation by RT-qPCR (Fig. 1g).
Distinct patterns of IgG versus dextran distribution
To examine whether IgG simply followed CSF and inter-
stitial fluid (ISF) flow, fluorescein-conjugated dextran
(40,000 MW) was injected intrathecally to mice. We ob-
served a distribution pattern similar to that described by
Iliff et al. [18] (not shown). We then examined the effect
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of a sterile needle insertion to the striatum. No change
in distribution of dextran was observed when it was
intrathecally injected into mice 1 day after sterile needle
insertion (Fig. 2a). Importantly, we did not observe dex-
tran deposition in the area around the needle insertion
(Fig. 2c), although we observed increased GFAP staining
at this site (Fig. 2c, white arrow). This indicates that al-
tered CSF/ISF flow was not directly responsible for the
pattern of IgG deposition seen following needle inser-
tion. Analysis of expression levels of genes associated
with the renin-angiotensin system and with inducible ni-
tric oxide synthase 1 day post needle insertion also
showed no change (not shown).
Pathogenic IgG induces NMOSD-like pathology
We asked whether intrathecally injected pathological
human antibodies would result in NMOSD-like
pathology at the insertion site. Mice received NMO-
IgG together with complement by intrathecal injec-
tion, or as controls NMO-IgG alone or normal-IgG
with complement, 1 day post needle insertion. All
groups showed significant deposition of human IgG
at the insertion site in the ipsilateral hemisphere
1 day after the intrathecal injection (Fig. 3a). A low
level of IgG deposition was detected at higher mag-
nification throughout the areas adjacent to the inter-
face with the CSF, possibly indicating passive
diffusion of IgG from CSF to the parenchyma. This
diffusion of IgG was strongest in mice that received
NMO-IgG and complement, although was also de-
tected in mice receiving NMO-IgG or normal-IgG +
C (Fig. 3b). This low-level deposition did not result
in noticeable loss of AQP4 or GFAP staining (not
shown). Analysis of IgG deposition 3 days after
intrathecal injection revealed that it was still signifi-
cant at the insertion site for both NMO-IgG +
Fig. 1 IgG trafficking is influenced by needle insertion. a–f Representative histological micrographs of frontal brain sections from mice showing IgG
distribution in and around the needle track following intrathecal injection of normal-IgG 1, 2, 3, or 7 days after sterile needle insertion. Sections show higher
deposition of IgG 1 day post needle insertion compared to later time points. g Comparison of relative expression of inflammation-associated cytokines (IL-
10, TGFβ, IL-4, IFNγ, and TNFα) between the cortex and striatum from mice 1 day post needle insertion and unmanipulated (unm) mice. Data were
analyzed by two-tailed nonparametric Student’s t test followed by the Mann–Whitney test. Results are presented as means ± SEM. Bar 200 μm
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complement and for controls (Fig. 3c). However, the
low-level IgG diffusion seen 1 day after intrathecal
injection was now absent (Fig. 3d). Furthermore,
1 day post intrathecal injection complement-
dependent NMOSD-like pathology was observed at
the site of sterile needle insertion in mice that re-
ceived NMO-IgG and complement (3/3). Pathology
was identified by loss of AQP4 and GFAP staining
on astrocytes together with deposition of human-
IgG and activated complement (C9neo) (Fig. 3e).
One mouse that received NMO-IgG alone by intra-
thecal injection (1/4) showed loss of AQP4 and
GFAP staining together with deposition of IgG and
C9neo, suggesting unusual fixation of endogenous
complement in this case (not shown). We also
assessed BBB breakdown by intravenous injection of
HRP. As expected, diffusion of HRP was observed
associated to the needle track (not shown) and in
association to NMO-like pathology (not shown).
Discussion
In this study, we have shown that independent of patho-
genicity and complement, a sterile needle insertion di-
rects deposition of CSF-derived IgG in the brain
parenchyma. Time intervals between needle insertion
and intrathecal injection of human IgG were shown to
be crucial to the extent of IgG deposition, deposition
peaking transiently 1 day after needle insertion. We ob-
served complement-dependent astrocyte pathology at
the needle insertion site induced by intrathecally deliv-
ered NMO-IgG and complement, identified as loss of
staining for the astrocytic markers AQP4 and GFAP to-
gether with deposition of IgG and activated complement.
Consistent with our previous study [14], we observed
HRP leakage from blood to parenchyma in and close to
the needle track and together with astrocytic pathology.
Cellular infiltration was not marked. Importantly, intra-
thecally delivered dextran did not show the same
localization. Expression levels of cytokines associated
with inflammation were not affected by needle insertion,
except for TNFα which was significantly upregulated.
TNFα has previously been shown to be upregulated after
injury in both adult and neonatal mouse brain [22].
Detection of AQP4-IgG in CSF has been reported in
NMOSD, and disease activity has been linked to high
levels of AQP4-IgG in CSF and serum [9, 10, 23]. Fur-
thermore, levels of AQP4-IgG in CSF strongly correlate
with astrocyte damage, as reflected in elevated levels of
soluble GFAP in CSF during NMO relapse [10, 24]. We
have previously reported that NMO-IgG and comple-
ment injected intrathecally deposited in three patterns.
We observed deposition in leptomeninges, subarachnoid
space, and the subpial spaces where vessels penetrate the
brain parenchyma [14]. The previously observed lepto-
meningeal deposition of NMO-IgG is in line with the
observation that contrast enhancement of the leptomen-
ingeal structures, indicating disruption of the leptomen-
ingeal blood-barrier, has been observed in AQP4-IgG-
positive patients during clinical attacks [25]. The ob-
served distribution pattern of IgG was similar for
normal-IgG and NMO-IgG. We also observed depos-
ition in the periventricular region for both normal- and
NMO-IgG. Interestingly, we observed perivascular de-
position specifically for NMO-IgG and complement at
brain parenchymal vessels distal from the site of paren-
chymal entry of pial vessels. This perivascular deposition
was associated with astrocyte pathology and together
with blood-borne HRP leakage into the parenchyma in-
dicated that NMO-IgG in CSF has potential widespread
distribution within the brain via a paravascular route to
exert pathologic effects [14]. In this study, we also ob-
served HRP leakage together with astrocyte pathology.
We propose that IgG intrathecally injected after needle
insertion can distribute from CSF to parenchyma via
Fig. 2 Dextran does not deposit at needle insertion. a
Representative frontal brain section of a mouse intrathecally
injected with fluoresceinated dextran (40,000 MW) 1 day post
sterile needle insertion. The section was co-stained anti-GFAP
(red). Dextran was not observed in and around the needle
track. b and c show higher magnification of the contralateral
and ipsilateral hemispheres, respectively. GFAP staining (red) was
used to identify the needle track (white arrow). Bar 100 μm
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two different routes. One route would be via the above
identified paravascular route, while the other route
would be diffusion to parenchyma via the needle track.
It has been postulated that CSF flow is cardiac cycle-
dependent and not unidirectional [19, 26, 27]. In principle,
change in blood flow might affect the CSF flow, and a
change in CSF flow could explain why antibodies deposited
at the insertion site. However, examination of expression
levels of iNOS and elements of the renin-angiotension sys-
tem that are implicated in regulation of blood flow in the
brain showed no change. Furthermore, intrathecal injection
of a fluorescent dextran tracer showed no change in distri-
bution between naïve mice and mice 1 day post needle
insertion, indicating that CSF/ISF flow was not noticeably
affected by the needle insertion. Increased AQP4 and GFAP
immunoreactivities around the lesions were indeed ob-
served, as also seen in clinical and experimental studies with
or without needle insertion [11, 13]. However, this trauma-
induced increased immunoreactivity of AQP4 cannot by it-
self explain the loss of AQP4 that we observed. Normal-
IgG, which does not include antibodies against AQP4, is
also deposited around the needle insertion site, so upregula-
tion of AQP4 cannot explain the IgG-specific deposition.
The precise mechanism leading to deposition of IgG in and
around the needle stick remains unclear. However, there ap-
pears to be selectivity for IgG deposition since a dextran
Fig. 3 NMOSD-like pathology at the needle insertion. a, b Representative sagittal brain sections from mice intrathecally injected with NMO-IgG and
complement, NMO-IgG alone, or normal-IgG with complement 1 day post needle insertion. a Micrograph showing IgG deposition in and around the
needle track 1 day after intrathecal injection. b Low-level deposition of IgG away from the needle track 1 day after intrathecal injection. c, d Representative
sagittal brain sections from mice intrathecally injected with NMO-IgG and complement, NMO-IgG alone, or normal-IgG and complement 1 day post needle
insertion. c Micrograph showing IgG deposition in and around the needle track 3 days after intrathecal injection. d Lack of low-level deposition of IgG away
from the needle track 3 days after intrathecal injection. e NMO-like pathology in mice 3 days after intrathecal injection. Mice received NMO-IgG and
complement by intrathecal injection 1 day post needle insertion. Pathology was identified by loss of AQP4 and GFAP staining (brown) together with
deposition of IgG and activated complement (C9neo) (brown). Bars 200 μm (a, c), 100 μm (e), and 50 μm (b, d)
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tracer did not replicate these patterns. The mechanistic
basis for this selectivity is unknown but may reflect Fc re-
ceptors or other Ig-binding structures in the CNS [28, 29].
This study confirms our previous finding that both
NMO-IgG and normal-IgG diffuse from the CSF into the
parenchyma after intrathecal injection via cisterna magna
[14]. The low-level parenchymal IgG deposition bordering
the CSF distal from the needle insertion that we observed
after intrathecal injection is consistent with our previous
study showing parenchymal IgG deposition 2 days post
intrathecal injection [14]. Differences between the studies
may reflect that whereas the localization of pathology and
antibody distribution following intrathecal injection in our
previous work [14] reflected three different deposition pat-
terns, in the current study, a robustly predictable focus was
created experimentally. Another study found that both
NMO-IgG and normal-IgG were deposited in CNS paren-
chyma of rats when antibodies were continuously infused
into the right ventricle using an osmotic mini pump [30]. In
contrast, others found that when antibodies were infused
into the intrathecal space in the spinal cord of rats and
mice, only NMO-IgG infusion resulted in parenchymal de-
position [31, 32].
Our observations suggest that IgG in CSF is distrib-
uted selectively from subarachnoid spaces to brain par-
enchyma at the site of an injury. We speculate that
regional predilection of NMO lesions may reflect a com-
bination of constitutive microenvironmental effects and
external influences such as local infection which may
also contribute to the localization of IgG deposition. The
needle insertion that we have used is an experimental
approach to model this hypothesis. Once the mechanism
is established for IgG localization using experimental
systems such as the one we describe, then the role of
these different influences can be investigated.
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